For decades we treated inflammation in ALS, Parkinson disease, and Alzheimer disease as a secondary response to dying neurons. New evidence shows microglial activation is an early driver of disease, not just a cleanup crew arriving late. If we want to slow these diseases, we need to target neuroinflammation directly.